Development and Validation of the Modified Version of VascuQol Scale in Patients With Lower Extremity Peripheral Arterial Disease.
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06223217, who can take part
Where in China
- RenJi HospitalShanghai, ChinaContact: Jingpu ZhuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT06223217
- Record updated
- 25 January 2024
- Original description
The purpose of this study is to assess the utility of the Modified version of VascuQol Scale as an effective biopsychosocial assessment tool for patients suffering from lower extremity peripheral arterial disease.Read full original descriptionShow less
The purpose of this study is to assess the utility of the Modified version of VascuQol Scale as an effective biopsychosocial assessment tool for patients suffering from lower extremity peripheral arterial disease.
Inclusion: Male or female aged 18-90; The patient is diagnosed with lower extremity peripheral arterial disease; The patient is willing to comply with specified follow-up evaluations at the specified times; The patient understands the nature of the procedure and provides written informed consent before enrolment in the study; Before enrolment, the guidewire has crossed the target lesion; No restrictions on Rutherford grading, TASC grading, GLASS grading.
Exclusion: The patient is currently participating in another investigational drug or device study that has not reached the primary endpoint; Patients with other diseases that may seriously affect the quality of life, such as tumors, severe liver disease, cardiac insufficiency, etc., or those with a life expectancy of less than 2 years; Pregnant women or Female patients with potential childbearing; Patients unwilling or refusing to sign informed consent.